|
Originally published In Press as doi:10.1074/jbc.M006883200 on April 16, 2001
J. Biol. Chem., Vol. 276, Issue 26, 24331-24340, June 29, 2001
Pathogenic Neisseria Trigger Expression of Their
Carcinoembryonic Antigen-related Cellular Adhesion Molecule 1 (CEACAM1;
Previously CD66a) Receptor on Primary Endothelial Cells by Activating
the Immediate Early Response Transcription Factor, Nuclear
Factor- B*
Petra
Muenzner §,
Michael
Naumann§,
Thomas F.
Meyer §¶, and
Scott D.
Gray-Owen **
From the Max-Planck-Institut für Biologie,
Abteilung Infektionsbiologie, Spemannstrasse 34, 72076 Tübingen,
the § Max-Planck-Institut für Infektionsbiologie,
Abteilung Molekulare Biologie, Schumannstrasse 21/22, Berlin (Mitte)
D-10117, Germany, and the Department of Medical Genetics and
Microbiology, University of Toronto, Toronto M5S 1A8, Canada.
Received for publication, August 1, 2000, and in revised form, February 15, 2001
 |
ABSTRACT |
Neisseria gonorrhoeae express
opacity-associated (Opa) protein adhesins that mediate binding to
various members of the carcinoembryonic antigen-related cellular
adhesion molecule (CEACAM; previously CD66) receptor family.
Although human umbilical vein endothelial cells express little CEACAM
receptor in vitro, we found neisserial infection to induce
expression of CEACAM1, CEACAM1-3L, and CECAM1-4L splice
variants. This mediates an increased
Opa52-dependent binding of gonococci by these
cells. The induced receptor expression did not require bacterial Opa
expression, but it was more rapid with adherent bacteria. Because the
time course of induction was similar to that seen for induced
proinflammatory cytokines, we tested whether CEACAM1 expression could
be controlled by a similar mechanism. Gonococcal infection activated a
nuclear factor- B (NF- B) heterodimer consisting of p50 and p65,
and inhibitors that prevent the nuclear translocation of activated
NF- B complex inhibited CEACAM1 transcript expression. Each of these
effects could be mimicked by using culture filtrates or purified
lipopolysaccharide instead of intact bacteria. Together, our results
support a model whereby the outer membrane "blebs" that are
actively released by gonococci trigger a Toll-like receptor-4-dependent activation of NF- B, which
up-regulates the expression of CEACAM1 to allow
Opa52-mediated neisserial binding. The regulation of
CEACAM1 expression by NF- B also implies a broader role for this
receptor in the general inflammatory response to infection.
 |
INTRODUCTION |
The important human pathogens Neisseria
gonorrhoeae and Neisseria meningitidis possess the
ability to colonize human mucosal tissue and then penetrate into deeper
tissues to cause invasive disease. Initial contact with host tissues is
thought to be mediated by neisserial type IV pili, and a tight
secondary interaction can then be established by the bacteria's
phase-variable, colony opacity-associated
(Opa)1 outer membrane proteins.
There are two distinct classes of Opa proteins based on their
differential binding specificity for cellular receptors. One class
targets the Neisseriae to cell surface heparan sulfate
proteoglycan (HSPG) receptors (1, 2) and, via binding to the
extracellular matrix proteins vitronectin and fibronectin, to cell
surface integrins (3, 4). Other Opa proteins bind to the CD66
epitope-containing members of the
carcinoembryonic antigen-related cellular adhesion molecules (CEACAM),
which are expressed differentially on multiple tissues throughout the
human host (5, 6). Some Opa proteins interact with both HSPG and CEACAM
receptors (7, 8), presumably via distinct binding sites; however, each
variant appears to be able to mediate host cellular invasion only via
either one or the other receptor class (9).
CEACAM1 (previously called BGP or CD66a; new nomenclature for this and
other CEA family members was introduced by Beauchemin et al.
(42)), CEACAM3 (CGM1 or CD66d), CEACAM5 (CEA or CD66e), and
CEACAM6 (NCA or CD66c) can all serve as receptors for the pathogenic
Neisseria spp.; however, individual Opa variants are specific for various combinations of these closely related proteins (7, 8, 10). The closely related receptors CEACAM4, CEACAM7, and CEACAM8
are not bound by any Opa variants tested to date (16). Each CEACAM
receptor consists of an immunoglobulin variable domain-like region
followed by up to six immunoglobulin constant domain-like structures
(6). CEACAM1 and CEACAM3 are inserted into the cellular membrane via a
carboxyl-terminal transmembrane and cytoplasmic domain, whereas
CEACAM5, CEACAM6, CEACAM7, and CEACAM8 possess glycosylphosphatidylinositol anchors. Even though each receptor is
highly glycosylated, binding is a protein-protein interaction with Opa
proteins recognizing CEACAM residues exposed on the GFCC' face of the
amino-terminal domain (17). These different binding specificities may
have important implications for the pathogenic process of
Neisseria because the distribution pattern of each CEACAM
receptor should influence the cellular tropism of neisserial strains
expressing different Opa variants in vivo. In addition, very
different cellular processes have been linked to individual CEA family
members (6, 18), suggesting that the cellular response to
neisserial binding depends upon the specific combination of CEACAM
receptors engaged.
Even though CEACAM receptors are part of the immunoglobulin
superfamily, their functions are poorly understood. They mediate intercellular adhesion via both homotypic (CEACAM1, CEACAM5, and CEACAM6) and/or heterotypic (CEACAM5-CEACAM6 and CEACAM6-CEACAM8) interactions (22, 23). CEACAM1 and CEACAM6 are also involved in the
adherence of activated neutrophils to cytokine-activated endothelial cells, both directly through their ability to present the sialylated Lewisx antigen to E-selectin and indirectly by the
CEACAM6-stimulated activation of CD18 integrins (18). The role of
CEACAM receptors is not, however, restricted to simple anchorage to
adjacent cells because various receptors can influence cell cycle
control and cellular differentiation. For example, CEACAM1 expression
inhibits the proliferation of mouse colonic carcinoma cells both
in vitro and in vivo, and this effect was
abrogated by deleting the receptor's cytoplasmic domain
(24, 25). Such a growth-inhibitory role is consistent with
clinical observations that CEACAM1 expression is down-regulated in
various colonic carcinomas (26, 27). Together, these features imply a
role for members of the CEACAM receptor family as sensory and
regulatory molecules in cell-cell adhesion events (28).
CEACAM1, CEACAM3, and CEACAM6 are expressed by human polymorphonuclear
neutrophils and can mediate gonococcal binding and opsonin-independent
phagocytosis by these phagocytes (10, 11, 14, 29). This interaction
appears to play a central role in the pathogenic process because a
urethral exudate consisting primarily of polymorphonuclear neutrophils
associated with both extracellular and intracellular attached gonococci
is the hallmark of gonorrhea. CEACAM receptors expressed by other cells
also appear to play an important role during other stages of neisserial
infection. Polarized T84 epithelial cells express CEACAM1, CEACAM5, and
CEACAM6 on their apical surface, and Opa binding to these receptors
mediates bacterial uptake, cellular transcytosis, and release at the
basolateral surface (30). This is consistent with previous findings
that N. gonorrhoeae and N. meningitidis appear in
the subepithelial layers following the in vitro infection of
organ cultures (31). Because both of these pathogens can also cause
invasive disease, interactions with the endothelia must also occur.
Primary human umbilical vein endothelial cells (HUVECs) grown in
culture express little CEACAM receptor. There is, however, a
substantial up-regulation of CEACAM1 expression after treatment with
the proinflammatory cytokine tumor necrosis factor (TNF- ) (13, 15, 32), which is present in serum at high levels during invasive
meningococcal disease (33). This increased up-regulation of CEACAM1
correlates with an increased adherence and invasion of different
Opa-expressing bacteria into these cells in vitro (13, 15).
In the present study, we observed that prolonged infection of HUVECs
resulted in an increased binding of gonococci expressing the CEACAM
receptor-specific Opa52 adhesin. We have shown previously
that N. gonorrhoeae infection induces TNF- expression by
epithelial cells (36). If a similar response occurs during neisserial
infection of endothelial cells, then these bacteria could presumably
induce an autocrine loop that results in the expression of CEACAM1. We
thus determined the kinetics of CEACAM1 expression pattern after
neisserial infection and related these to the induced cytokine profile.
We demonstrate that the CEACAM1-4L and
CECAM1-3L splice variants are both induced with a
time course similar to that of proinflammatory cytokines, including TNF- . Our results indicate that the activation of nuclear factor kappa B (NF- B) directly triggers CEACAM1 expression and mediates increased Opa-dependent bacterial binding to HUVECs. This
phenomenon could clearly contribute to neisserial attachment to and
penetration into the vasculature during invasive disease. It also has
broad implications for our understanding of the natural role of CEACAM1 because its regulation by the immune regulator factor NF- B implies a
role in the innate response of endothelial cells to infection. This
represents the first example that we are aware of in which a human
pathogen directly induces the expression of its receptor by a target
host cell.
 |
MATERIALS AND METHODS |
Cell Lines--
HUVECs were obtained from human umbilical vein
by chymotrypsin digestion as described previously (37) and then grown
in low serum endothelial cell growth medium (PromoCell, Heidelberg,
Germany) using flasks precoated with 0.2% gelatin in a humidified
atmosphere at 37 °C with 5% CO2. HUVECs at passage 4 were grown to form a confluent monolayer and then seeded to new
precoated flasks or into wells containing gelatin-coated glass
coverslips to obtain a confluence of about 60%. Human dermal
microvascular endothelial cells (HDMECs) were cultured in MCDB-131
medium (Life Technologies, Inc.) with 10% heat-inactivated fetal calf
serum and used between passages 4 and 5.
Bacterial Strains--
Construction of the recombinant strains
invariantly synthesizing the 11 genetically defined Opa proteins of
N. gonorrhoeae MS11 were described previously by Kupsch
et al. (9). The cloned opa genes were
expressed in the genetic background of the MS11 derivative N279, which
lacks pili and carries a deletion in the epithelial cell
invasion-associated opaC30 locus. Daily subculture of all
strains was carried out using a binocular microscope to select for
desired Opa phenotypes. Opa protein expression patterns were confirmed
by SDS-polyacrylamide gel electrophoresis and immunoblot analysis of
total bacterial extracts using the monoclonal antibody 4B12C11 (38),
which was generously provided by Dr. Mark Achtman (Berlin, Germany).
Recombinant Escherichia coli strains expressing N. meningitidis Opa variants were also described previously (15).
Bacterial Infection Assays and Stimulation of HUVECs--
For
infection experiments, HUVECs were seeded into 75-cm2
flasks to obtain cultures at about 70% confluence at the time of infection. One night before infection, the medium was changed to M199
(Life Technologies, Inc.) supplemented with 10% fetal calf serum.
Gonococci were harvested from fresh overnight cultures into M199 medium
containing 10% heat-inactivated fetal calf serum to obtain a culture
density of 108 colony-forming units/ml and then used
to infect HUVECs at a multiplicity of infection of 10-20 bacteria/cell
for the indicated time points. For immunofluorescence analysis, HUVECs
were infected as outlined above except that cells were initially seeded
onto gelatin-coated 12-mm glass coverslips, and the samples were fixed
after the final washing step postinfection by incubating in 3.7%
paraformaldehyde in 200 mM HEPES buffer, pH 7.4, for 30 min
at room temperature. To determine the levels of gonococcal adherence
and invasion, the gonococci were stained for immunofluorescence and
then analyzed by confocal laser scanning microscopy as described
previously (15, 30). Where indicated, various other stimuli were added
directly to the culture medium. TNF- was purchased from R&D Systems.
Where indicated, purified mouse anti-human TNF- monoclonal
antibodies (BD PharMingen, San Diego) were added at 15 µg/ml just
prior to infection. The polyclonal anti-human CEACAM antiserum was
puchased from DAKO (Glostrup, Denmark). Experiments involving LPS were done using LPS prepared from E. coli serotype O111:B4 and/or
Salmonella typhimurium by phenol extraction (Sigma). LPS
suspensions were sonicated in endotoxin-free water (Life Technologies,
Inc.) to disperse any aggregates formed and were then diluted to the
indicated final concentration in supplemented medium. Neisserial LPS
was purified according to the method of Galanos et al.
(62) and was generously provided by Dr. Anne Muller from our
group (Berlin).
Immunoblotting--
CEACAM1 protein expression in response to
exposure to bacterial strains, TNF- , or other stimuli was determined
by immunoblot analysis of total cellular protein essentially as
described before (15). Protein concentration in each sample was
determined by colorimetric Bradford protein assay (Bio-Rad), and equal
amounts of protein were separated by SDS-polyacrylamide gel
electrophoresis (10-11%) and blotted onto Immobilon P transfer
membranes (Millipore). Western blot analysis was performed using the
CEACAM1, CEACAM3, CEACAM5, and CEACAM6 cross-specific monoclonal
antibody D14HD11, the CEACAM6-specific antibody 9A6 (Immunotech,
Marseille, France), and the CEACAM1 and CEACAM5 cross-specific antibody
4/3/17. D14HD11 and 4/3/17 were both generously provided by Dr. Fritz
Grunert, University of Freiburg, Germany. Bound antibodies were
detected using a peroxidase-conjugated goat anti-mouse secondary
antibody and the ECL chemiluminescent detection system (Amersham
Pharmacia Biotech).
To test for I B degradation, cytosolic fractions obtained from
HUVECs exposed to various stimuli were analyzed by immunoblot analysis
using an I B -specific polyclonal antibody that does not
cross-reactive with other I B family members (C-21; Santa Cruz Biotechnology).
Inhibitor Experiments--
NF- B SN50 (BIOMOL Research
laboratories, Inc.) is a cell-permeable peptide that inhibits the
translocation of active NF- B complex into the nucleus. Cells were
pretreated with 50 µg/ml of this peptide for 15 min at 37 °C
before TNF- or the bacteria were added. To confirm the role of
NF- B in CEACAM1 expression, two other inhibitors with different
mechanisms of action were also used. The cells were pretreated either
with the serine protease inhibitor tosylphenylalanyl chloromethyl
ketone (TPCK; Sigma) or a proteasome inhibitor (PSI) obtained from
Calbiochem-Novabiochem Ltd. (U. K.) for 30 min before addition of the stimuli.
To inhibit phosphorylation-dependent steps involved in the
activation of NF- B, HUVECs seeded in 75-cm2 flasks were
either not pretreated or were pretreated with 1 µM herbimycin A for 24 h or 100 mM genistein for 1 h
and then either infected with N309 or stimulated with TNF- . The
effects of these inhibitors on CEACAM1 expression levels were then
determined as indicated.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Analysis--
Total RNA was isolated from HUVECs that had been treated
with various stimuli, as indicated, using either Trizol reagent (Life Technologies, Inc.) or the Qiagen RNEasy Kit, as outlined by the manufacturers, and then treated further with RNase-free DNase-I. Equal
amounts of RNA were reverse transcribed into single-stranded cDNA
using Superscript IIRT (Life Technologies, Inc.) and oligo(dT) primers.
As a control, the synthesis of cDNA was performed in the absence of
reverse transcriptase. Subsequent amplification of CEACAM1 was carried
out using CEACAM1-specific primers for 30 cycles at 56 °C annealing
temperature. The differential amplification of CEACAM1 splice variants
was performed using Taq polymerase (Life Technologies, Inc.)
for 33 cycles with an annealing temperature of 56 °C. The primers
used were 5'-primer B1 (ACAGTCAAGACGATCATAGT) and 3'-primer C2
(ATCTTGTTAGGTGGGTCATT), resulting in amplified fragments of between 189 and 530 bp (39). Amplification of cytokine DNA was done using the
primers that we have described previously (36). To detect Toll-like
receptor (TLR) expression, PCR amplification of the cDNA template
was performed using Taq polymerase for 28 cycles at 95 °C
for 40 s, 54 °C for 40 s, and 72 °C for 1 min. PCR
primers used for TLR-2 were GCCAAAGTCTCTTGATTGATTCC and
TTGAAGTTCTCCAGCTCCTG, and those used for TLR-4 were
TGGATACGTTTCCTTATAAG and GAAATGGAGGCACCCCTTC (40). Depending on
which primer sets were used for the primary amplification, primers
specific for the constitutively expressed housekeeping gene GAPDH or
-actin was also included within the reaction mixture to provide an
internal control that allowed samples to be loaded equally. In each
case, PCR products were visualized by ethidium bromide staining after
agarose gel electrophoresis.
Electrophoretic Mobility Shift Assay--
At the indicated time
points after infection, cytoplasmic and nuclear extracts were prepared
by using the non-ionic detergent method described previously (36). Gel
retardation assays for the detection of active NF- B complex were
performed using an Ig oligonucleotide that had been labeled using
the large fragment DNA polymerase (Klenow) in the presence of
deoxy-[ -32P]ATP. The DNA binding reactions were
performed in 20 µl of binding buffer for 20 min at 30 °C.
Competition experiments and supershift assays were performed with
antibodies as described previously (36). The reaction products were
analyzed by electrophoresis in a 5% polyacrylamide gel using 12.5 mM Tris, 12.5 mM boric acid, and 0.25 mM EDTA, pH 8.3, and the gels were then dried and exposed to Amersham TM films (Amersham Pharmacia Biotech) at 70 °C using an intensifying screen.
 |
RESULTS |
Neisserial Infection Induces CEACAM1 Expression by Endothelial
Cells--
Previously, we had found very little CEACAM1 receptor
expression by HUVECs unless they were prestimulated with the
proinflammatory cytokine TNF- . Other members of the CEA receptor
family were not found in either unstimulated or stimulated HUVECs.
Consistent with this, N. gonorrhoeae or recombinant E. coli expressing either gonococcal or meningococcal CEACAM-specific
Opa proteins showed only low levels of binding to HUVECs using standard
(i.e. 3 h) in vitro infection assays unless
the HUVECs were pretreated with TNF- (13, 15). However, we found
that extended infection resulted in consistently increasing levels of
Opa-mediated bacterial binding to otherwise unstimulated HUVECs, and
this correlated with an increased level of bacterial internalization
(Fig. 1A). To demonstrate that the
increased binding was caused by interactions with CEACAM receptor(s),
HUVECs were pretreated with polyclonal anti-CEACAM antibody prior to
infection. This treatment blocked interaction with the HUVECs almost
completely, and the increased bacteria binding with time was no
longer evident (Fig. 1B).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
CEACAM-dependent association of
N. gonorrhoeae with primary endothelial cells
increases with time. HUVECs seeded on glass coverslips were
infected with N309/Opa52 over a time period from 1 to
24 h. At the indicated time points, cells were fixed and then
labeled immunofluorescently for analysis by confocal laser scanning
microscopy. Panel A, total associated and intracellular
bacteria/cell were counted. Black bars show adherence to
untreated HUVECs; open bars show intracellular bacteria
associated with untreated HUVECs. Panel B, HUVECs seeded
on glass coverslips were pretreated with 100 µg/ml anti-CEACAM
antibody (Ab) for 1 h (cross-hatched bars)
or left untreated (black bars). HUVECs were then infected
with N309/Opa52 over a time period from 1 to 24 h, and
total associated bacteria/cell is shown. Assays were performed in
triplicate on at least three separate occasions, and data illustrate
the mean ± S.D. of one representative experiment.
|
|
To determine whether these increased interactions could result from
increased CEACAM receptor expression, we performed immunoblot analysis
of cellular lysates prepared at various intervals after infection. The
HUVECs were either left untreated, infected with various gonococcal
strains, or stimulated with TNF- as a positive control. Expression
of the CEACAM1 protein was found to be induced during neisserial
infection, and the time course of this induction was similar to that
seen when stimulating the cells with purified TNF- (Fig.
2A). No other CEACAM family
member(s) were detected in either stimulated or unstimulated cells. The
rapid induction of CEACAM1 expression after infection was also
confirmed by FACS analysis (data not shown) and by semiquantitative
RT-PCR to detect CEACAM1-encoding transcript (Fig. 2B).
Importantly, N. gonorrhoeae strains expressing either the
HSPG receptor-specific Opa50 or the CEACAM
receptor-specific Opa52, and the nonadherent
Opa strain N302 induced CEACAM1 expression (Fig. 2,
A and B). This implies that this effect was not
likely the result of a specific signal directly downstream of Opa
binding to one of its cellular receptors. We generally observed
increased levels of three defined protein bands by immunoblot analysis
using the CEACAM receptor-specific monoclonal antibody D14HD11 (Fig.
2A) and have confirmed that all three bands represent the
CEACAM1 receptor by comparing blots probed with various CEACAM-specific
antibodies (data not shown). This banding pattern likely results from a
combination of the variable glycosylation of CEACAM1 and/or the
expression of multiple splice variants because the relative levels of
each of these can vary among cells and cell lines (41). 13 different
CEACAM1 splice variants are known to exist. To analyze which splice
variant(s) are induced in endothelial cells, we performed RT-PCR
experiments with RNA from unstimulated, TNF- -treated, and
gonococcal-infected HUVECs. The primer pair used amplifies the mRNA
fragment that spans from the middle of the Ig constant domain-like B1
region to the carboxyl-terminal end of the cytoplasmic domain. Using these primers, it is possible to discriminate among known splice variants according to the size of the RT-PCR products (39). Stimulated endothelial cells were found to express only 2 of the 13 known splice
variants, as shown in Fig. 2C. The larger RT-PCR product revealed a size of 531 bp, which corresponds to CEACAM1-4L
(BGPa) expression, whereas the second RT-PCR product (242 bp) indicates that the CEACAM1-3L (BGPb) splice variant which lacks the A2
domain, is also expressed. Both splice variants were expressed in equal amounts (Fig. 2C), and each contains both the amino-terminal
domain, which is bound by Opa proteins, and the long cytoplasmic
domain, which contains the immunoreceptor tyrosine-based inhibitory
motif-like sequences (42). The same pattern of splice variants was
observed whether the HUVECs were treated with TNF- (Fig. 2C) or
infected with N. gonorrhoeae N303/Opa50 (data
not shown).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 2.
Effect of N. gonorrhoeae
infection on CEACAM expression by HUVECs. Panel
A, HUVECs were either left untreated, infected with different
gonococcal strains (N303/Opa50, N309/Opa52,
N302/Opa ), or stimulated with 10 ng/ml TNF- . Total
protein was isolated at the indicated time points, separated by
SDS-polyacrylamide gel electrophoresis, and immunoblots were probed
with the CEACAM receptor-specific monoclonal antibody D14HD11.
Panel B, CEACAM1 transcript expression by HUVECs.
Total RNA was isolated after the indicated time intervals following the
addition of TNF- or gonococcal infection and then reverse
transcribed into single-stranded cDNA. Amplification of DNA was
carried out by PCR using a CEACAM1-specific primer pair. In
each case, the transcript encoding the housekeeping protein GAPDH was
coamplified as an internal control to assure that equal samples were
applied. Panel C, expression of the CEACAM1-4L (BGPa) and
CECAM1-3L (BGPb) splice variants by HUVECs. HUVECs were either left
untreated, infected with gonococcal strain N309/Opa52, or
stimulated with 10 ng/ml TNF- . Total RNA was isolated after 2 h
and reverse transcribed into cDNA. The expression of
CEACAM1 splice variants was assessed by semiquantitative PCR
amplification from the resulting template. The coamplification of
-actin transcript was used as an internal control to confirm that
equal amounts of cDNA were applied. These data are representative
for at least three independent experiments. The schematic drawings that
illustrate the domain structure of CEACAM1-4L and -3L are used here
with the permission of Fritz Grunert (University of Freiburg,
Germany).
|
|
We have shown previously that TNF- expression by epithelial cells is
induced by gonococcal infection (36). If this also happens in HUVECs,
then an autocrine loop involving de novo TNF- expression which leads to the subsequent induction of CEACAM1 expression could
presumably explain the increased gonococcal binding seen in Fig. 1. To
assess changes in cytokine gene expression in response to gonococcal
infection of endothelial cells, we used specific primers to perform
semiquantitative RT-PCR from total RNA isolated at various time points
after infection (Fig. 3). N. gonorrhoeae strains expressing either no Opa (N302),
Opa52 (N309), or Opa50 (N303) induced the
expression of several cytokines, including IL-1 , IL-6, IL-8, and
TNF- , whereas the expression levels of other cytokines did not
change. Because CEACAM1 expression was induced as quickly as any of
these cytokines (i.e. compare Figs. 2B and 3), it
is unlikely that newly expressed cytokines are responsible for the
induced CEACAM1 receptor expression. However, because we have shown
previously that TNF- stimulates CEACAM1 expression (13, 15), we
determined that induced TNF- was required for CEACAM1 expression by
using antibodies that inhibit the activity of TNF- . These antibodies
clearly reduced CEACAM1 protein expression in response to TNF-
treatment but not in response to neisserial infection (Fig.
4), thus confirming that this cytokine is not essential for the induced receptor expression.

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 3.
Analysis of cytokine mRNA levels in
HUVECs in response to N. gonorrhoeae infection.
Total RNA isolated from HUVECs that had either been left untreated
or were infected by different gonococcal strains for the indicated
times was analyzed by RT-PCR using cytokine-specific primer pairs, as
indicated. -Actin mRNA primers were included in each reaction as
an internal control to assure equal loading, and the amplified
-actin transcript is indicated (*). Similar results were obtained in
more than three independent experiments. GM-CSF,
granulocyte-macrophage colony-stimulating factor; MCP-1,
monocyte chemoattractant protein 1; TGF- , transforming
growth factor ; Rantes, regulated on activation normal T
cell expressed and secreted.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 4.
TNF- expressed by
infected HUVECs is not required for the induced expression of
CEACAM1. HUVECs were either infected with N309/Opa52
or stimulated by the addition of 20 ng/ml TNF- , each in the presence
(+) or absence ( ) of 15 µg/ml anti-human TNF- monoclonal
antibody (Ab). As a control HUVECs were left untreated.
Total protein was isolated at the indicated time points,
separated by SDS-polyacrylamide gel electrophoresis, and immunoblots
were probed with either the CEACAM receptor-specific monoclonal
antibody D14HD11 or I B -specific antibody, respectively. Similar
results were obtained in more than three independent experiments.
|
|
Neisserial Infection Activates NF- B in Endothelial
Cells--
Proinflammatory cytokines are controlled by the immediate
early transcription factor NF- B. NF- B is normally found in the cytoplasm as a complex with I B, which blocks NF- B translocation to the nucleus and thus prevents transcription of NF-kB regulated genes. Upon cellular activation, I B dissociates from NF- B and is
degraded by the proteasome, thereby allowing translocation of the
released NF- B into the nucleus. Subconfluent monolayers of HUVECs
were treated with TNF- or infected with N. gonorrhoeae expressing either the HSPG-specific Opa50 or the
CEACAM-specific Opa52. At different time points after
challenge, the cells were harvested and fractionated to separate the
cytosol from the nuclei. The resulting nuclear protein extracts were
then analyzed for the levels of DNA binding activity using an
electrophoretic mobility shift assay with a radioactively labeled
oligonucleotide corresponding to the DNA binding site of NF- B (Fig.
5A). Nuclear protein binding of
the oligonucleotide was observed within 10 min of infection by
N303/Opa50, and this increased until 90 min postinfection
before declining again by 180 min. N309/Opa52 also induced
NF- B activation, although this happened after a short delay
(i.e. by 45 min). TNF- treatment of the HUVECs resulted
in a more rapid translocation of NF- B, with strong binding being
observed by 10 min postinfection. The time course of active NF- B
appearing in the nuclear fraction following each of these stimuli
correlated well with the disappearance of I B from in the cytosol
(Fig. 5B). Consistent with the CEACAM1 protein expression
being independent of TNF- expressed by the infected HUVECs (Fig.
4A), anti-TNF- antibodies clearly reduced I B
degradation in response to added TNF- but had little effect on that
seen in response to neisserial infection (Fig. 4B).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 5.
N. gonorrhoeae infection activates
the transcription factor NF- B. HUVECs
were either infected with various gonococcal strains, stimulated with
10 ng/ml TNF- , or left untreated (Uninf). At the
indicated time points, cells were harvested and fractionated to obtain
the cytosolic fraction and the high salt extract of nuclei, as
described under "Materials and Methods." Panel A, the
nuclear extracts were incubated with radioactively labeled DNA fragment
(Ig ), which contains the NF- B binding site, and then subjected to
native polyacrylamide gel electrophoresis and autoradiography. The
specificity of NF- B·DNA complex formation was investigated
by competition (Comp) with the indicated amounts of
unlabeled oligonucleotide. The composition of the induced NF- B
complex was investigated by antibody supershifts using anti-p50,
anti-p65, anti-c-Rel antisera or control preimmune serum
(Preserum). The positions of the protein-DNA complexes are
indicated. The data are representative of at least three independent
experiments. Panel B, cytosolic fractions were prepared from
samples taken at different time points after infection or stimulation
with TNF- . Untreated HUVECs were used as a control. The samples were
then probed by Western blot analysis using an I B -specific
antibody.
|
|
We then performed competition band shift assays using the unlabeled
oligonucleotide consensus sequence to confirm the specificity of the
binding activity seen, and a decrease in the formation of
radioactively labeled complex was observed with increasing concentration of unlabeled NF- B consensus sequence (Fig.
5A). Because several different homodimeric or heterodimeric
forms of NF- B exist, the nature of the activated transcription
factor was characterized using supershift assays (Fig. 5A).
Experiments were performed in which the nuclear extracts were
preincubated with anti-p50, anti-p65, anti-c-Rel, or preimmune serum
before addition of the 32P-labeled oligonucleotide
containing the B sequence. The reduced mobility of bound
oligonucleotide in the presence of anti-p50 and anti-p65 antibodies
indicates that these subunits represent the predominant protein species
in the B DNA-binding complex that becomes activated by gonococcal infection.
To determine whether CEACAM1 expression is controlled directly by
NF- B, we tested whether various inhibitors of NF- B function influenced CEACAM1 expression after HUVEC stimulation with TNF- and/or gonococcal infection. We observed an inhibition of CEACAM1 transcript expression when the cells were pretreated with either the
serine protease inhibitor TPCK or a PSI that inhibits the 20 S
proteasome (Fig. 6B) and a
corresponding reduction in CEACAM1 protein seen by Western blot (Fig.
6A). An inhibitory effect was also seen by Western blot
(Fig. 6C) and semiquantitative RT-PCR (data not shown) when
the cells were pretreated with an inhibitory peptide (NF- B SN50)
that inhibits the nuclear translocation of activated NF-kB complex.
Consistent with this, NF- B SN50 reduced the apparent increase in
CEACAM-dependent bacterial binding seen during prolonged
infection (Fig. 7). TPCK, PSI, and the
NF- B-specific peptide all inhibit NF- B induction of transcription
by different mechanisms, and the fact that each also inhibits CEACAM1
expression clearly indicates that NF- B is involved in the control of
CEACAM1 expression.

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 6.
N. gonorrhoeae-induced expression
of CEACAM1 is blocked by inhibitors of NF- B
activation. Panel A, HUVECs were pretreated with 25 µM TPCK or 50 µM PSI for 30 min, as
indicated. The cells were subsequently infected with
N303/Opa50, N309/Opa52, or treated with 10 ng/ml TNF- . Untreated HUVECs (Uninf) were used as a
control. The cell lysates were harvested and analyzed by Western blot
analysis using the CEACAM receptor-specific monoclonal antibody
D14HD11. Panel B, effect of TPCK and PSI on
CEACAM1 transcript expression. Total RNA was isolated from
HUVECs at the indicated time points after infection with gonococcal
strains or stimulation with TNF- , and then CEACAM1
expression levels were assessed by semiquantitative RT-PCR. Expression
of the housekeeping gene encoding GAPDH was used as an internal
control. Panel C, HUVECs were infected with N. gonorrhoeae or stimulated using TNF- in the presence or absence
of the cell-permeable inhibitory peptide SN50, which contains the NLS
sequence of the NF- B p50 subunit, as indicated. Untreated HUVECs
were used as a control. The cell lysates were harvested and analyzed by
Western blot analysis using the CEACAM receptor-specific monoclonal
antibody D14HD11. The Coomassie Blue-stained figure was included to
confirm that variations in CEACAM1 expression were not caused by
differences in sample loading. The data are representative of at least
three independent experiments.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
NF-kB activity is required for the increased
association of N. gonorrhoeae with HUVECs over
time. HUVECs seeded onto glass coverslips were treated with 50 µg/ml inhibitory peptide NF- B SN50 (cross-hatched bars)
or left untreated (black bars) for 30 min prior to infection
by N309/Opa52. At the indicated times, samples were fixed
and analyzed by confocal laser scanning microscopy to determine total
associated bacteria/cell. The untreated control in this figure and in
Fig. 1B are the same because the anti-CEACAM antibody and
the SN50 inhibitor samples were performed in parallel. This assay was
performed in triplicate on at least three separate occasions, and data
illustrate the mean ± S.D. of one representative
experiment.
|
|
A tyrosine kinase-dependent step has been reported to occur
upstream of NF- B activation in some systems (43, 44) but not in
others (45). We therefore tested whether the broadly specific tyrosine
kinase inhibitor genistein and/or the Src family kinase-specific inhibitor herbimycin A had an effect on CEACAM1 expression (Fig. 8). Both inhibitors down-regulated the
sustained expression of CEACAM1 transcript after treatment with either
TNF- or gonococci, although low levels of transcript were still
detected at early time points (i.e. 0.5 and 2 h
postinfection) in the presence of these inhibitors.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of protein tyrosine kinase inhibitors
on the expression of CEACAM1. HUVECs were
untreated or pretreated with 1 µM herbimycin A
(HMA) for 24 h or 100 µM genistein for
1 h, infected with N309/Opa52, or treated with 10 ng/ml TNF- . Total RNA was isolated at the indicated time points and
analyzed by RT-PCR using GAPDH expression as an internal control.
Similar results were obtained in more than three independent
experiments.
|
|
Characterization of a Neisserial Factor That Activates
NF- B--
The finding that CEACAM1 expression was induced by
gonococci regardless of the receptor specificity of their expressed Opa (Fig. 2) suggests that NF- B activation is not a specific response triggered by simple engagement of one of these receptors. The fact that
the Opa strain N302 also induces CEACAM1 expression (Fig.
2) also implies that bacterial binding to the HUVECs is not necessary.
To test whether the factor that activates NF-kB is released into the
culture supernatant, we passed cultures of gonococcal strain
N303/Opa50 through a 0.2-µm filter to remove intact
bacteria but not soluble factors released by the gonococci. At various
intervals after the addition of filtrate to the HUVECs, total cellular
protein was isolated and analyzed. A clear induction of CEACAM1 was
seen to follow exposure of HUVECs to gonococcal filtrates (Fig.
9A), and there was no obvious
difference with respect to the time course of this effect
versus that seen in response to infection by whole bacteria
(i.e. compare with Fig. 2A).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 9.
Induction of CEACAM1 expression by
N. gonorrhoeae strain N303/Opa50culture
filtrates. HUVECs were seeded onto six-well plates in triplicate.
The cells were then treated with either filtrates that had been
prepared by passing N303/Opa50 cultures through a
0.22-µm-pore filter (panel A) or 1 µg/ml purified LPS
(panel B). At the indicated times, total cell lysates were
then isolated from HUVECs, and CEACAM1 expression was assessed by
Western blot analysis using the CEACAM receptor-specific monoclonal
antibody D14HD11. HUVECs cultured in medium alone or in medium
supplemented with 10 mg/ml TNF- were used as negative and positive
controls, respectively. The data are representative of at least three
independent experiments.
|
|
Gonococci are known to shed large amounts of outer membrane in the form
of "blebs" that contain both LPS and outer membrane proteins. LPS
is a potent activator of cells of the immune and inflammatory systems,
including macrophage, monocytes, and endothelial cells. It is bound by
the serum LPS-binding protein, and this complex is then bound by the
CD14 receptor (46, 47). Endothelial cells do not express CD14, but
instead use soluble CD14 from serum to respond to LPS (48). We thus
tested whether purified LPS could itself mediate the induction of
CEACAM1 expression. As seen during neisserial infection, purified LPS
triggered both the disappearance of I B by 1.5 h (data not
shown) and the subsequent expression of CEACAM1 by 2.5 h (Fig.
9B). We tested various concentrations of LPS that had been
purified from various bacterial species with similar results (data not
shown). Neither the membrane-bound (mCD14) nor the serum-soluble
(sCD14) LPS receptors are themselves competent to induce intracellular
signaling or downstream cellular responses to LPS. Recently, it has
been reported that the sCD14·LPS-binding protein complex interacts
with distinct members of the TLR family. In particular, TLR-4 appears
to mediate the activation of NF- B in response to LPS (49, 50). The
closely related TLR-2 has been shown to induce a similar cellular
response in the presence of other cell wall components (55, 60). We
thus confirmed that our HUVECs expressed these receptors by using
semiquantitative RT-PCR. We found TLR-2 and TLR-4 both to be expressed
(Fig. 10), however we did not find an
obvious difference in the levels of expression of these two receptors
such as was reported previously (51). Consistent with the previous
work, we did see obvious differences in the levels of TLR-2 and TLR-4
message in HDMEC (Fig. 10), suggesting that differences in endothelial
cell source and/or growth conditions may effect the relative expression
levels of TLR receptors seen. Our data do, however, confirm that TLR-2
and TLR-4 are both expressed by the HUVECs cell lines used in our
studies and may thus mediate the NF- B activation and CEACAM1
expression that results from neisserial infection.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 10.
Primary endothelial cell expression of
TLRs. TLR-2 and TLR-4 expression was assessed by semiquantitative
RT-PCR using total RNA extracted from HUVECs and HDMECs. Primers
specific for -actin were included in the reaction mixture as an
internal control. HDMECs were used as an independent source of human
TLR mRNA expression to confirm the differences reported previously
in the relative expression of TLR-2 and TLR-4 in these cells (40). The
identities of PCR products obtained are indicated with
arrows. The results are representative of at least three
independent experiments.
|
|
 |
DISCUSSION |
In a previous study, we observed that treatment of primary
endothelial cells (HUVECs) with the proinflammatory cytokine TNF- resulted in an induction of CEACAM1 expression and a corresponding increase in adherence and host cellular invasion by Opa-expressing Neisseria (13, 15). The localized liberation of TNF- from
sites infected by other pathogens might render the inflamed tissues as
targets for colonization by CEACAM-binding strains. Such a phenomenon
might help to explain the clinical correlates that imply that an
increased risk of invasive meningococcal disease follows viral or other
infections of the nasopharyngeal mucosa. TNF- is present in serum at
high levels during disseminated infection (33). It may, therefore,
also contribute to the rapid progression of invasive neisserial disease
as the resulting up-regulation of CEACAM1 expression should facilitate
bacterial interactions with the vasculature. Such a detrimental effect
of TNF- expression on the outcome of invasive neisserial infection
is supported by the fact that the administration of anti-TNF-
antibodies to infected infant rats protects them against lethal
meningococcemia (53). The fact that Hemeophilus influenzae
is also capable of binding to CEACAM receptors (52) indicates that the
up-regulation of CEACAM1 may also influence the outcome of invasive
disease by this pathogen. In this context it is interesting to note
that the three most important agents of bacterial meningitis, N. meningitidis, H. influenzae, and Streptococcus
pneumoniae produce IgA1 proteases, and we recently found that
neisserial IgA1 protease is a potent stimulator of proinflammatory
cytokines in peripheral blood cells (54).
Here we demonstrate that the prolonged exposure of HUVECs to
gonococci resulted in an increased level of
Opa52- dependent bacterial binding, even in the
absence of adding exogenous cytokine (Fig. 1A). This implied
that the expression of one or more CEACAM receptor was being
up-regulated. Because we have previously observed an induction of
TNF- synthesis in cultured epithelial cells upon neisserial
infection (36), we initially speculated that a similar response from
endothelial cells could result in an autocrine loop that ultimately
resulted in the up-regulation of CEACAM receptor(s). However, we have
instead found that anti-TNF- antibodies have little effect on the
induction of CEACAM1 expression (Fig. 4) and that the expression of
CEACAM1 transcript is triggered as rapidly as that of any cytokine,
including TNF- (i.e. compare Figs. 2B and 3).
These results imply that CEACAM1 expression is induced directly. Our
previous evidence that the immediate early transcription factor NF- B
was central in the inflammatory response of epithelial cells to
gonococcal infection (36) thus prompted us to look whether it could
also directly control CEACAM1 expression. Gel retardation assays using
nuclear extracts isolated from infected HUVECs confirmed that
gonococcal infection does activate NF-kB in these cells (Fig. 5),
supershift experiments demonstrated that the active NF- B complex
consisted of a heterodimer consisting of the p50 and p65 subunits (Fig.
5), and the inactivation of NF- B by inhibitors blocked the
expression of CEACAM1 (Fig. 6). Together, these data indicate that
CEACAM1 is controlled directly by NF- B. This novel finding implies
an important role for this receptor in the endothelial cellular stress
response because CEACAM1 would be activated in coordination with
proinflammatory cytokines and other receptors that are involved in
immune activation. The ability of CEACAM1 to mediate both homotypic and
heterotypic interactions with other CEACAM family members might assist
in the recruitment of professional phagocytes and lymphocytes that
express one or more of these receptors (6, 39). Both CEACAM1 splice
variants induced by neisserial infection possess a cytoplasmic
immunoreceptor tyrosine inhibitory motif that has been shown previously
to arrest the growth of epithelial cells (24, 54). Whether their
expression also functions to arrest the growth of infected endothelial
cells remains to be determined.
The induction of CEACAM1 by N. gonorrhoeae did not require
Opa protein expression, suggesting that this effect was not a specific response triggered by bacteria binding to either the host cell HSPG or
CEACAM receptors. The ability of a strain to adhere to HUVECs did,
however, affect the rate of the host cellular response. This is
demonstrated most clearly by comparing the time course of I B
degradation (Fig. 5B) and the subsequent activation of NF- B (Fig. 5A) induced by infecting with strain N303,
which expresses the Opa50 adhesin and can adhere to HUVECs
via the HSPG receptors,2 and
N309, which expresses the CEACAM-specific Opa52 and thus requires CEACAM1 expression to be induced before effective binding can
occur: both responses are induced much more rapidly by N303. It was,
therefore, interesting that gonococcal culture filtrates triggered
CEACAM1 expression because this indicated that the stimulus was
released by the bacteria. N. gonorrhoeae actively releases large amounts of membrane blebs, which consist of both protein and lipid components of the outer membrane. Because endotoxin is a
potent activator of NF- B, we tested whether LPS could itself induce
CEACAM1 expression. LPS isolated from gonococci (data not shown),
S. typhimurium, or E. coli (Fig. 9) induced
CEACAM1 expression with a time course that was similar to that seen
with intact bacteria (Fig. 2), indicating that LPS is sufficient for
the observed induction of receptor. It is, however, important to
consider that although LPS is sufficient to induce CEACAM1 expression,
our results do not exclude the possibility that other bacterial
components may also contribute to this response. Endothelial cells
react to complexes of LPS and serum-soluble CD14 via TLR-4, which
induce an IL-1-like signal cascade that ends in the activation of NF-kB
(40, 50). Recent studies indicate that the related TLR-2 mediates the
cellular responses to microbial lipoproteins (55) and to cell wall
components other than LPS (60). We thus confirmed that each of these
receptors was expressed in our HUVECs by using semiquantitative RT-PCR. Their presence confirms that one or both could trigger a response that
ultimately activates NF- B.
Our results indicate that neisserial infection of primary endothelial
cells induces CEACAM1 expression via a pathway that is triggered by the
LPS-specific CD14 and TLR-4-dependent activation of NF- B
(Fig. 11). Bacteria that can adhere to the
endothelia by either the HSPG receptor-specific Opa50 or,
presumably, by pili, trigger this response more quickly than do
bacteria that express either no adhesin or CEACAM-specific Opa
proteins. These differences likely result from differences in the
efficiency of delivery of LPS and/or other soluble effectors because
adherent bacteria would presumably cause their local concentration to
be higher. The translocation of activated NF- B into the nucleus directly induces the expression of proinflammatory cytokines such as
IL-1, IL-6, and TNF- , and receptors, which function in the recruitment of immune cells, including the vascular cell adhesion molecule-1, E-selectin (61), and CEACAM1 (this work). Because various
cytokines can activate NF- B, it seems likely that the cytokines
expressed by infected endothelial cells will stimulate CEACAM1
expression further. Consistent with this premise, we did observe that
anti-TNF- antibody caused a slight reduction in the level of CEACAM1
produced at later time points (24 h; Fig. 4 and data not shown). This
did, however, constitute only a small fraction of the CEACAM1 seen in
these cells. The expression of CEACAM1 at the endothelial surface can
then mediate an increased Opa/CEACAM1-specific bacterial binding and
internalization (Ref. 15 and this work). To our knowledge, this process
represents the first example of a bacterial pathogen's ability to
autoinduce expression of its host cellular receptor. This remarkable
process has important implications for invasive disease because it
obviously can mediate interactions between Opa-expressing
Neisseria and the vasculature in vivo. Whether
its primary benefit to the bacteria is simple colonization or immune
evasion is still unclear; however, the coregulation of various other
inflammatory mediators with CEACAM1 presumably means that an immune
response is imminent. The induction of CEACAM1 may also be important
for other stages of infection because NF-kB is a ubiquitously expressed
transcription factor that could presumably allow neisserial induction
of CEACAM1 on tissues other than the endothelia. Together, these events
clearly represent yet another example of the complex interactions that have evolved between the pathogenic Neisseria and humans,
their only natural host.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 11.
Schematic model showing N. gonorrhoeae induction of CEACAM1 receptor expression through
a NF- B-dependent pathway. LPS
liberated from adherent or nonadherent infecting gonococci, likely in
the form of membrane blebs, triggers a signal cascade through TLR-4
which ultimately leads to the degradation of I B . The nuclear
translocation of activated NF- B allows direct induction of the
expression of immune mediators, including proinflammatory cytokines
(e.g. TNF- , IL-1 ) and receptors involved in the
recruitment of immune cells, including vascular cellular adhesion
molecule 1, E-selectin, and CEACAM1. The newly expressed CEACAM1 allows
the gonococci to establish a tight, Opa protein-dependent
anchorage to the endothelia and may lead to bacterial uptake into
the target cell. A more detailed description of this model is presented
under "Discussion."
|
|
 |
ACKNOWLEDGEMENTS |
We are grateful to Silja Wessler for support
in the electrophoretic mobility shift assay and to Andreas Popp for
helpful discussions throughout this work.
 |
FOOTNOTES |
*
This study was supported in part by Deutsche
Forschungsgemeinschaft Grants Me705/5-1 and Na292/5-2 and by the Fonds
der Chemischen Industrie.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed in Berlin.
Tel.: 49-030-2846-0402; Fax: 49-030-2846-0401; E-mail:
meyer@mpiib-berlin.mpg.de.
**
Supported by Medical Research Council of Canada Grant MT-15499.
Published, JBC Papers in Press, April 16, 2001, DOI 10.1074/jbc.M006883200
2
M. Dehio, E. Freissler, K. T. Kreisner, C. Dehio, and T. F. Meyer, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
Opa, opacity-associated;
HSPG, heparan sulfate proteoglycan;
CEACAM, carcinoembryonic antigen-related cellular adhesion molecule;
HUVECs, human umbilical vein endothelial cells;
TNF- , tumor necrosis factor
;
NF- B, nuclear factor B;
HDMECs, human dermal microvascular
endothelial cells;
LPS, lipopolysaccharide;
I B , inhibitory
protein B ;
TPCK, tosylphenylalanyl chloromethyl
ketone;
PSI, proteasome inhibitor;
RT-PCR, reverse
transcription-polymerase chain reaction;
bp, base pairs;
TLR, Toll-like
receptor;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
IL, interleukin.
 |
REFERENCES |
| 1.
|
Chen, T.,
Belland, R. J.,
Wilson, J.,
and Swanson, J.
(1995)
J. Exp. Med.
182,
511-517
|
| 2.
|
van Putten, J. P.,
and Paul, S. M.
(1995)
EMBO J
14,
2144-2154
|
| 3.
|
Dehio, M.,
Gomez-Duarte, O. G.,
Dehio, C.,
and Meyer, T. F.
(1998)
FEBS Lett.
424,
84-88
|
| 4.
|
Duensing, T. D.,
and van Putten, J. P.
(1997)
Infect. Immun.
65,
964-970
|
| 5.
|
Prall, F.,
Nollau, P.,
Neumaier, M.,
Haubeck, H. D.,
Drzeniek, Z.,
Helmchen, U.,
Loning, T.,
and Wagener, C.
(1996)
J. Histochem. Cytochem.
44,
35-41
|
| 6.
|
Thompson, J. A.,
Grunert, F.,
and Zimmermann, W.
(1991)
J. Clin. Lab. Anal.
5,
344-366
|
| 7.
|
Chen, T.,
Grunert, F.,
Medina-Marino, A.,
and Gotschlich, E. C.
(1997)
J. Exp. Med.
185,
1557-1564
|
| 8.
|
Virji, M.,
Evans, D.,
Hadfield, A.,
Grunert, F.,
Teixeira, A. M.,
and Watt, S. M.
(1999)
Mol. Microbiol.
34,
538-551
|
| 9.
|
Kupsch, E. M.,
Knepper, B.,
Kuroki, T.,
Heuer, I.,
and Meyer, T. F.
(1993)
EMBO J.
12,
641-650
|
| 10.
|
Virji, M.,
Makepeace, K.,
Ferguson, D. J.,
and Watt, S. M.
(1996)
Mol. Microbiol.
22,
941-950
|
| 11.
|
Chen, T.,
and Gotschlich, E. C.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
14851-14856
|
| 12.
|
Bos, M. P.,
Grunert, F.,
and Belland, R. J.
(1997)
Infect. Immun.
65,
2353-2361
|
| 13.
|
Gray-Owen, S. D.,
Lorenzen, D. R.,
Haude, A.,
Meyer, T. F.,
and Dehio, C.
(1997)
Mol. Microbiol.
26,
971-980
|
| 14.
|
Gray-Owen, S. D.,
Dehio, C.,
Haude, A.,
Grunert, F.,
and Meyer, T. F.
(1997)
EMBO J.
16,
3435-3445
|
| 15.
|
Muenzner, P.,
Dehio, C.,
Fujiwara, T.,
Achtman, M.,
Meyer, T. F.,
and Gray-Owen, S. D.
(2000)
Infect. Immun.
68,
3601-3607
|
| 16.
|
Popp, A.,
Dehio, C.,
Grunert, F.,
Meyer, T. F.,
and Gray-Owen, S. D.
(1999)
Cell. Microbiol.
1,
169-181
|
| 17.
|
Billker, O.,
Popp, A.,
Gray-Owen, S. D.,
and Meyer, T. F.
(2000)
Trends Microbiol.
8,
258-261
|
| 18.
|
Kuijpers, T. W.,
Hoogerwerf, M.,
van der Laan, L. J.,
Nagel, G.,
van der Schoot, L. E.,
Grunert, F.,
and Roos, D.
(1992)
J. Cell Biol.
118,
457-466
|
| 19.
|
Eidelman, F. J.,
Fuks, A.,
DeMarte, L.,
Taheri, M.,
and Stanners, C. P.
(1993)
J. Cell Biol.
123,
467-475
|
| 20.
|
Klein, M. L.,
McGhee, S. A.,
Baranian, J.,
Stevens, L.,
and Hefta, S. A.
(1996)
Infect. Immun.
64,
4574-4579
|
| 21.
|
Kleinerman, D. I.,
Dinney, C. P.,
Zhang, W. W.,
Lin, S. H.,
Van, N. T.,
and Hsieh, J. T.
(1996)
Cancer Res.
56,
3431-3435
|
| 22.
|
Benchimol, S.,
Fuks, A.,
Jothy, S.,
Beauchemin, N.,
Shirota, K.,
and Stanners, C. P.
(1989)
Cell
57,
327-334
|
| 23.
|
Oikawa, S.,
Inuzuka, C.,
Kuroki, M.,
Arakawa, F.,
Matsuoka, Y.,
Kosaki, G.,
and Nakazato, H.
(1991)
J. Biol. Chem.
266,
7995-8001
|
| 24.
|
Kunath, T.,
Ordonez-Garcia, C.,
Turbide, C.,
and Beauchemin, N.
(1995)
Oncogene
11,
2375-2382
|
| 25.
|
Hsieh, J. T.,
Luo, W.,
Song, W.,
Wang, Y.,
Kleinerman, D. I.,
Van, N. T.,
and Lin, S. H.
(1995)
Cancer Res.
55,
190-197
|
| 26.
|
Neumaier, M.,
Paululat, S.,
Chan, A.,
Matthaes, P.,
and Wagener, C.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
10744-10748
|
| 27.
|
Kleinerman, D. I.,
Troncoso, P.,
Lin, S. H.,
Pisters, L. L.,
Sherwood, E. R.,
Brooks, T.,
von Eschenback, A. C.,
and Hsieh, J. T.
(1995)
Cancer Res.
55,
1215-1220
|
| 28.
|
Obrink, B.
(1997)
Curr. Opin. Cell Biol.
9,
616-626
|
| 29.
|
Hauck, C. R.,
Lorenzen, D.,
Saas, J.,
and Meyer, T. F.
(1997)
Infect. Immun.
65,
1863-1869
|
| 30.
|
Wang, J.,
Gray-Owen, S. D.,
Knorre, A.,
Meyer, T. F.,
and Dehio, C.
(1998)
Mol. Microbiol.
30,
657-671
|
| 31.
|
McGee, Z. A.,
Stephens, D. S.,
Hoffman, L. H.,
Schlech, W. F.,
and Horn, R. G.
(1983)
Rev. Infect. Dis.
5,
S708-S714
|
| 32.
|
Majuri, M. L.,
Hakkarainen, M.,
Paavonen, T.,
and Renkonen, R.
(1994)
APMIS
102,
432-438
|
| 33.
|
Waage, A.,
Halstensen, A.,
and Espevik, T.
(1987)
Lancet
1,
355-357
|
| 34.
|
Waage, A.,
Brandtzaeg, P.,
Halstensen, A.,
Kierulf, P.,
and Espevik, T.
(1989)
J. Exp. Med.
169,
333-338
|
| 35.
|
Girardin, E.,
Grau, G. E.,
Dayer, J. M.,
Roux-Lombard, P.,
and Lambert, P. H.
(1988)
N. Engl. J. Med.
319,
397-400
|
| 36.
|
Naumann, M.,
Wessler, S.,
Bartsch, C.,
Wieland, B.,
and Meyer, T. F.
(1997)
J. Exp. Med.
186,
247-258
|
| 37.
|
Dehio, C.,
Meyer, M.,
Berger, J.,
Schwarz, H.,
and Lanz, C.
(1997)
J. Cell Sci.
110,
2141-2154
|
| 38.
|
Achtman, M.,
Neibert, M.,
Crowe, B. A.,
Strittmatter, W.,
Kusecek, B.,
Weyse, E.,
Walsh, M. J.,
Slawig, B.,
Morelli, G.,
and Moll, A.
(1988)
J. Exp. Med.
168,
507-525
|
| 39.
|
Kammerer, R.,
Hahn, S.,
Singer, B. B.,
Luo, J. S.,
and von Kleist, S.
(1998)
Eur. J. Immunol.
28,
3664-3674
|
| 40.
|
Zhang, F. X.,
Kirschning, C. J.,
Mancinelli, R.,
Xu, X. P.,
Jin, Y.,
Faure, E.,
Mantovani, A.,
Rothe, M.,
Muzio, M.,
and Arditi, M.
(1999)
J. Biol. Chem.
274,
7611-7614
|
| 41.
|
Hefta, S. A.,
Paxton, R. J.,
and Shively, J. E.
(1990)
J. Biol. Chem.
265,
8618-8626
|
| 42.
|
Beauchemin, N.,
Drabert, P.,
Dveksler, G.,
Gold, P.,
Gray-Owen, S. D.,
Grunert, F.,
Hammarstrom, S.,
Holmes, K. V.,
Karlsson, A.,
Kuroki, M.,
Lin, S.-H.,
Lucka, L.,
Naijar, M.,
Neumaier, M.,
Obrink, B.,
Shively, J. E.,
Skubitz, K. M.,
Stanners, C. P.,
Thomas, P.,
Thompson, J. A.,
Virji, M.,
von Kleist, S.,
Wagener, C.,
Watt, S.,
and Zimmermann, W.
(1999)
Exp. Cell Res.
252,
243-249
|
| 43.
|
Mahon, T. M.,
and O'Neill, L. A.
(1995)
J. Biol. Chem.
270,
28557-28564
|
| 44.
|
Zen, K.,
Karsan, A.,
Eunson, T.,
Yee, E.,
and Harlan, J. M.
(1998)
Exp. Cell Res.
243,
425-433
|
| 45.
|
Delude, R. L.,
Fenton, M. J.,
Savedra, R. J.,
Perera, P. Y.,
Vogel, S. N.,
Thieringer, R.,
and Golenbock, D. T.
(1994)
J. Biol. Chem.
269,
22253-22260
|
| 46.
|
Pugin, J.,
Schurer-Maly, C. C.,
Leturcq, D.,
Moriarty, A.,
Ulevitch, R. J.,
and Tobias, P. S.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
2744-2748
|
| 47.
|
Ulevitch, R. J.,
and Tobias, P. S.
(1994)
Curr. Opin. Immunol.
6,
125-130
|
| 48.
|
Arditi, M.,
Zhou, J.,
Dorio, R.,
Rong, G. W.,
Goyert, S. M.,
and Kim, K. S.
(1993)
Infect. Immun.
61,
3149-3156
|
| 49.
|
Chow, J. C.,
Young, D. W.,
Golenbock, D. T.,
Christ, W. J.,
and Gusovsky, F.
(1999)
J. Biol. Chem.
274,
10689-10692
|
| 50.
|
Faure, E.,
Equils, O.,
Sieling, P. A.,
Thomas, L.,
Zhang, F. X.,
Kirschning, C. J.,
Polentarutti, N.,
Muzio, M.,
and Arditi, M.
(2000)
J. Biol. Chem.
275,
11058-11063
|
| 51.
|
Tapping, R. I.,
Akashi, S.,
Miyake, K.,
Godowski, P. J.,
and Tobias, P. S.
(2000)
J. Immunol.
165,
5780-5787
|
| 52.
|
Virji, M.,
Evans, D.,
Griffith, J.,
Hill, D.,
Serino, L.,
Hadfield, A.,
and Watt, S. M.
(2000)
Mol. Microbiol.
36,
784-795
|
| 53.
|
Nassif, X.,
Mathison, J. C.,
Wolfson, E.,
Koziol, J. A.,
Ulevitch, R. J.,
and So, M.
(1992)
Mol. Microbiol.
6,
591-597
|
| 54.
|
Lorenzen, D. R.,
Düx, F.,
Wölk, U.,
Tsirpouchtsidis, A.,
Haas, G.,
and Meyer, T. F.
(1999)
J. Exp. Med.
190,
1049-1058
|
| 55.
|
Luo, W.,
Wood, C. G.,
Earley, K.,
Hung, M. C.,
and Lin, S. H.
(1997)
Oncogene
14,
1697-1704
|
| 56.
|
Schwandner, R.,
Dziarski, R.,
Wesche, H.,
Rothe, M.,
and Kirschning, C. J.
(1999)
J. Biol. Chem.
274,
17406-17409
|
| 57.
|
Brightbill, H. D.,
Libraty, D. H.,
Krutzik, S. R.,
Yang, R. B.,
Belisle, J. T.,
Bleharski, J. R.,
Maitland, M.,
Norgard, M. V.,
Plevy, S. E.,
Smale, S. T.,
Brennan, P. J.,
Bloom, B. R.,
Godowski, P. J.,
and Modlin, R. L.
(1999)
Science
285,
732-736
|
| 58.
|
Hirschfeld, M.,
Kirschning, C. J.,
Schwandner, R.,
Wesche, H.,
Weis, J. H.,
Wooten, R. M.,
and Weis, J. J.
(1999)
J. Immunol.
163,
2382-2386
|
| 59.
|
Means, T. K.,
Wang, S.,
Lien, E.,
Yoshimura, A.,
Golenbock, D. T.,
and Fenton, M. J.
(1999)
J. Immunol.
163,
3920-3927
|
| 60.
|
Underhill, D. M.,
Ozinsky, A.,
Hajjar, A. M.,
Stevens, A.,
Wilson, C. B.,
Bassetti, M.,
and Aderem, A.
(1999)
Nature
401,
811-815
|
| 61.
|
Baldwin, A. S. J.
(1996)
Annu. Rev. Immunol.
14,
649-683
|
| 62.
|
Galanos, C.,
Lüderitz, O.,
and Westphal, O.
(1969)
Eur. J. Biochem.
9,
245-249
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. J. Callaghan, C. Buckee, N. D. McCarthy, A. B. Ibarz Pavon, K. A. Jolley, S. Faust, S. J. Gray, E. B. Kaczmarski, M. Levin, J. S. Kroll, et al.
Opa Protein Repertoires of Disease-Causing and Carried Meningococci
J. Clin. Microbiol.,
September 1, 2008;
46(9):
3033 - 3041.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Bookwalter, J. A. Jurcisek, S. D. Gray-Owen, S. Fernandez, G. McGillivary, and L. O. Bakaletz
A Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Homologue Plays a Pivotal Role in Nontypeable Haemophilus influenzae Colonization of the Chinchilla Nasopharynx via the Outer Membrane Protein P5-Homologous Adhesin
Infect. Immun.,
January 1, 2008;
76(1):
48 - 55.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Yu, E. M. C. Chow, H. Wong, J. Gu, O. Mandelboim, S. D. Gray-Owen, and M. A. Ostrowski
CEACAM1 (CD66a) Promotes Human Monocyte Survival via a Phosphatidylinositol 3-Kinase- and AKT-dependent Pathway
J. Biol. Chem.,
December 22, 2006;
281(51):
39179 - 39193.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.-M. Bamberger, J. Briese, J. Gotze, I. Erdmann, H. M. Schulte, C. Wagener, and P. Nollau
Stimulation of CEACAM1 expression by 12-O-tetradecanoylphorbol-13-acetate (TPA) and calcium ionophore A23187 in endometrial carcinoma cells
Carcinogenesis,
March 1, 2006;
27(3):
483 - 490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Servin
Pathogenesis of Afa/Dr Diffusely Adhering Escherichia coli
Clin. Microbiol. Rev.,
April 1, 2005;
18(2):
264 - 292.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Betis, P. Brest, V. Hofman, J. Guignot, I. Kansau, B. Rossi, A. Servin, and P. Hofman
Afa/Dr Diffusely Adhering Escherichia coli Infection in T84 Cell Monolayers Induces Increased Neutrophil Transepithelial Migration, Which in Turn Promotes Cytokine-Dependent Upregulation of Decay-Accelerating Factor (CD55), the Receptor for Afa/Dr Adhesins
Infect. Immun.,
April 1, 2003;
71(4):
1774 - 1783.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. Maisey, G. Nardocci, M. Imarai, H. Cardenas, M. Rios, H. B. Croxatto, J. E. Heckels, M. Christodoulides, and L. A. Velasquez
Expression of Proinflammatory Cytokines and Receptors by Human Fallopian Tubes in Organ Culture following Challenge with Neisseria gonorrhoeae
Infect. Immun.,
January 1, 2003;
71(1):
527 - 532.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Caamano and C. A. Hunter
NF-{kappa}B Family of Transcription Factors: Central Regulators of Innate and Adaptive Immune Functions
Clin. Microbiol. Rev.,
July 1, 2002;
15(3):
414 - 429.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Tato and C. A. Hunter
Host-Pathogen Interactions: Subversion and Utilization of the NF-{kappa}B Pathway during Infection
Infect. Immun.,
July 1, 2002;
70(7):
3311 - 3317.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. B. Singer, I. Scheffrahn, R. Heymann, K. Sigmundsson, R. Kammerer, and B. Obrink
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Expression and Signaling in Human, Mouse, and Rat Leukocytes: Evidence for Replacement of the Short Cytoplasmic Domain Isoform by Glycosylphosphatidylinositol-Linked Proteins in Human Leukocytes
J. Immunol.,
May 15, 2002;
168(10):
5139 - 5146.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Muenzner, O. Billker, T. F. Meyer, and M. Naumann
Nuclear Factor-kappa B Directs Carcinoembryonic Antigen-related Cellular Adhesion Molecule 1 Receptor Expression in Neisseria gonorrhoeae-infected Epithelial Cells
J. Biol. Chem.,
February 22, 2002;
277(9):
7438 - 7446.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|